Sentence examples for ms changes from inspiring English sources

Based on work in isolated mitochondria, the MCU and mNCX pathways could certainly not respond quickly enough to the very rapid (ms) changes in [Ca2+]c that occur during excitation-contraction (EC) coupling.

To find out whether the kinetics of the Ca2+-dependent switch-on/switch-off of cTn rate-limit the dynamics of myofibrillar force development and/or relaxation, force kinetics of myofibrils exchanged with NBD-cTn after rapid (within ∼10 ms) changes in [Ca2+] were determined in the mechanical setup.

In scenario 2, an MS changes its communication node from a base station (BS) to the RS of the same cell, or vice versa.

When low EC cell voltage is applied in on-line EC ESI MS, changes in ion intensities reflect changes in the oxidation conditions and are more apparent for 2e, 2H+ than for the 1e, 1H+ oxidation processes.

When a new MS enters/leaves the BS's coverage area or the profile of some MS changes, the BS generates a new user association, indicating the RS assigned to each MS for relaying service in the subsequent time slots.

Specifically, the user association specifies the RS assigned to each MS for relaying service in the subsequent time slots, which is static over certain period and updated by the proposed algorithm when a new MS enters/leaves the BS's coverage area or the profile of some MS changes.

It was found that the saturation magnetization Ms changed slightly at the range from 18 to 22 emu/cm3 with the annealing temperature increasing from 450 °C to 650 °C.

Further, while no-change trials were faster than change trials when the hands were near (11 ms), change trials were faster than no-change trials when the hands were away (28 ms).

The standard threshold used for the 3.5 ms change was 7 μV, whilst the optimised ones ranged from 4 9 μV.

Subjects had to detect an infrequent (2.7% of trials) rapid (200 ms) change (−30%) in the brightness of the fixation cross and indicate it via a button press.

A >500 ms change in QTcF was observed for a NEPA patient in cycles 1, 3 and 4 and an APR + PALO patient in cycle 6.